These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 30848039)

  • 1. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes.
    Kim K; Unni S; Brixner DI; Thomas SM; Olsen CJ; Sterling KL; Mitchell M; McAdam-Marx C
    Diabetes Obes Metab; 2019 Jul; 21(7):1725-1733. PubMed ID: 30848039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).
    Maegawa H; Ishigaki Y; Langer J; Saotome-Nakamura A; Andersen M;
    J Diabetes Investig; 2021 Mar; 12(3):374-381. PubMed ID: 32643314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O; Shaw JE; Blonde L; Paul SK
    Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
    Desouza C; Kirk AR; Mangla KK; Wolden ML; Lingvay I
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33376084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensification patterns and the probability of HbA
    Pantalone KM; Misra-Hebert AD; Hobbs TM; Ji X; Kong SX; Milinovich A; Weng W; Bauman JM; Ganguly R; Burguera B; Kattan MW; Zimmerman RS
    Diabet Med; 2020 Jul; 37(7):1114-1124. PubMed ID: 30653705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
    Fu AZ; Sheehan JJ
    Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43).
    Satoh J; Andersen M; Bekker Hansen B; Larsen Thorsted B; Tutkunkardas D; Zacho M; Maegawa H
    PLoS One; 2018; 13(9):e0198160. PubMed ID: 30226870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study.
    Fang HSA; Gao Q; Tan WY; Lee ML; Hsu W; Tan NC
    BMC Med; 2022 Jan; 20(1):22. PubMed ID: 35078484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
    Khunti K; Nikolajsen A; Thorsted BL; Andersen M; Davies MJ; Paul SK
    Diabetes Obes Metab; 2016 Apr; 18(4):401-9. PubMed ID: 26743666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study.
    Gómez-Peralta F; Carramiñana-Barrera F; Félix-Redondo FJ; Fraile-Gómez J;
    Int J Clin Pract; 2012 Oct; 66(10):959-68. PubMed ID: 22994330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting.
    Canivell S; Mata-Cases M; Real J; Franch-Nadal J; Vlacho B; Khunti K; Gratacòs M; Mauricio D
    Diabetes Obes Metab; 2019 Jun; 21(6):1373-1380. PubMed ID: 30756446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people.
    Khunti K; Wolden ML; Thorsted BL; Andersen M; Davies MJ
    Diabetes Care; 2013 Nov; 36(11):3411-7. PubMed ID: 23877982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based study.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabet Med; 2017 Feb; 34(2):213-222. PubMed ID: 27279380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.
    Abusnana S; Al Awadi F; Aly H; Bashier A; Kumar Dhanwal D; Halasa T; Jallo M; Medina J; Singhal S
    Diabetes Res Clin Pract; 2023 Feb; 196():110183. PubMed ID: 36436550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.